99 / 132
2015 Annual Report
99
Risk Assessment
Management and
Research Outcomes
Cosmetics
Management
Appendix
National
Laboratory and
Testing Network
Risk Communication
and Consumer
Protection
International
Cooperation and
Cross-Strait Exchange
Food
Management
Medicinal
Products
Management
Policy and
Organization
Controlled
Drugs
Management
Medical
Devices
Management
Medical and Medicinal Products Safety Management and Research
and Development Work Group
Pharmaceuticals and Cosmetics Work Group
Medical Devices Work Group
Health Food Work Group
Inspection and Testing Work Group
Conferences
Two meetings held every year by competent authorities
in Taiwan and Mainland China
(work meeting and supervisor meeting)
Technical Exchanges for Medicinal Product Testing
Cooperative Medicinal Product Research and Development
Figure 9-5
Structured platform for medicinal products established by Taiwan and Mainland China
Section 3. Cross-Strait Exchange
Current Status
Since the signing of the
Cross-strait Agreement on Food Safety
on 4 November 2008, TFDA has
held an
Expert Meeting of Competent Authorities
as well as
Cross-Strait Food Safety Agreement
- Import and Export Food Safety Meeting
with representatives from Mainland China in order to
exchange information on topics related to food standards and risk communication. For medical
and medicinal products, the
Cross-Strait Cooperation Agreement on Medicine and Public Health
Cooperation
was signed on 21 December 2010. Under this Agreement, the TFDA established a
Pharmaceutical Safety Management and R&D Working Group, and four Sub Working Groups for
Pharmaceuticals and Cosmetics; Medical Devices; Health Foods; and Testing and Verification. The
Agency also discussed bilateral cooperation mechanisms and established a platform for bilateral
institutional collaboration on pharmaceutical safety (Figure 9-5); improved cooperation on quality and
safety management, mechanisms for assistance with handling major pharmaceutical safety incidents,
and coordination to promote standards. It also realized ad-hoc collaboration in clinical trials, to
explore how to gradually adopt the implementation outcome of the other side, to make full use of the
pharmaceutical management and R&D capabilities on both sides, strengthen the quality and safety of
pharmaceuticals, and shorten the development process, so that the public has earlier access to safe
and effective pharmaceuticals in order to protect the health of people on both sides of the Strait.